24 June 2020 

Oxford University commenced human clinical trials for vaccine to treat Covid-19 in Brazil, according to sponsor Lemann Foundation. The trial has seen enrolment of 2,000 people in Sao Paulo and 1,000 people in Rio de Janeiro. Earlier this month, Brazilian health regulatory agency Anvisa had given its approval to the human clinical trials for this vaccine, which has been developed by Oxford and supported by AstraZeneca. Brazil has become the first country outside the UK to commence the trials of this vaccine candidate. Clinical researchers expect to introduce the vaccine to treat Covid-19 by the end of this year.

A small dose of the Covid-19 vaccine, developed by Imperial College London researchers, has been delivered to a first healthy volunteer at a west London facility. The team is monitoring the condition of the participant and reported that the participant is in good health with no safety issues. The vaccine is a part of £41m funding granted by the UK government and an additional £5m through philanthropy.

Symbiosis Pharmaceutical Services has signed a supply agreement with AstraZeneca for the manufacture of the Covid-19 recombinant adenovirus vaccine, which is known as AZD1222, for clinical trials. The agreement comes after AstraZeneca recently announced a licensing agreement with the University of Oxford for the development and distribution of the AZD1222 vaccine, which is currently undergoing clinical trials at several sites in the UK.

A Chinese-developed Covid-19 vaccine is claimed to have become the world’s first to have entered into a Phase III human clinical trial, which will commence in the UAE. This is the first overseas trial for this Covid-19 vaccine. The inactivated vaccine may consist of whole, inactivated agents developed by China National Pharmaceutical Group Sinopharm (Sinopharm), according to Globaltimes.